Form 4: Pelthos Therapeutics CFO Acquires Shares Following Reverse Stock Split

Pelthos Therapeutics Inc.'s Chief Financial Officer, Francis Knuettel II, acquired common stock and convertible preferred stock on July 1, 2025, following a 1-for-10 reverse stock split.

Summary

• Francis Knuettel II, Chief Financial Officer of Pelthos Therapeutics Inc. (PTHS), reported transactions on July 1, 2025.
• Acquired 10,000 shares of Common Stock indirectly through Camden Capital LLC at a price of $10 per share.
• Acquired 10,000 shares of Series A Convertible Preferred Stock, convertible at $10 per share, which underlies 10,000 shares of Common Stock. This acquisition was in connection with the cancellation of a promissory note.
• All reported numbers reflect a 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.
• Mr. Knuettel also beneficially owns 12,816 shares of Common Stock indirectly through the Lara Knuettel Revocable Trust.
• The Series A convertible preferred stock is convertible at any time, has no expiration date, and is subject to a contractual limitation such that the holder may not convert if it would result in beneficial ownership exceeding 4.99% of the common stock outstanding immediately after conversion.

Sentiment

Score: 4

Explanation: While insider buying can be seen as a positive signal of confidence, the primary corporate action disclosed, a 1-for-10 reverse stock split, is generally viewed negatively by the market as it often indicates underlying financial distress or a need to maintain listing compliance.

Positives

• Chief Financial Officer Francis Knuettel II acquired additional shares, potentially signaling confidence in the company's future prospects.
• The acquisition of Series A Convertible Preferred Stock was in connection with the cancellation of a promissory note, which could improve the company's balance sheet by reducing debt.

Negatives

• The company effected a 1-for-10 reverse stock split, which can often be perceived negatively by the market as it typically occurs when a stock's price is low or to meet exchange listing requirements, potentially indicating underlying challenges.

Risks

• The 1-for-10 reverse stock split may indicate underlying challenges such as a low share price or efforts to maintain listing compliance, which could signal financial instability or lack of investor confidence.
• The Series A convertible preferred stock is subject to a contractual limitation preventing conversion if it would result in beneficial ownership exceeding 4.99% of outstanding common stock, which could limit the holder's immediate flexibility to convert all preferred shares.

Future Outlook

No explicit forward-looking statements or guidance are provided.

Industry Context

This Form 4 filing details specific insider transactions and a corporate action (reverse stock split) for Pelthos Therapeutics Inc., rather than providing broader industry trends or competitive analysis.

Related Party Transactions

• Francis Knuettel II's beneficial ownership of shares is indirect through Camden Capital LLC and the Lara Knuettel Revocable Trust, entities where he holds managerial or trustee roles.

Stakeholder Impact

• Shareholders: The reverse stock split reduces the number of outstanding shares and increases the per-share price, but does not change the total value of their holdings. It might also signal efforts to maintain stock exchange listing.
• Creditors: The cancellation of a promissory note in exchange for preferred stock could reduce the company's debt obligations, potentially improving its financial health from a creditor's perspective.

Key Dates

Recommendation

Keywords

Pelthos Therapeutics, PTHS, SEC Form 4, insider trading, stock acquisition, reverse stock split, convertible preferred stock, beneficial ownership, Chief Financial Officer